

# Hans Prozesky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2258026/publications.pdf>

Version: 2024-02-01

81  
papers

14,872  
citations

108046

37  
h-index

78623

77  
g-index

84  
all docs

84  
docs citations

84  
times ranked

14688  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of laboratory-confirmed <scp>SARS-CoV-2</scp> infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. <i>Tropical Medicine and International Health</i> , 2022, 27, 564-573.	1.0	94
2	Modified Duke/European Society of Cardiology 2015 clinical criteria for infective endocarditis: time for an update?. <i>Open Heart</i> , 2022, 9, e001856.	0.9	8
3	Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. <i>Clinical Infectious Diseases</i> , 2021, 73, e2005-e2015.	2.9	405
4	Bartonella species as a cause of culture-negative endocarditis in South Africa. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1873-1879.	1.3	9
5	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. <i>Stroke</i> , 2021, 52, 1545-1556.	1.0	60
6	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. <i>JAMA Cardiology</i> , 2021, 6, 706.	3.0	53
7	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
8	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	13.9	2,143
9	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <scp>EMPEROR-Preserved</scp> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1798-1799.	2.9	21
10	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 924-932.	5.2	218
11	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. <i>The Lancet Global Health</i> , 2021, 9, e1216-e1225.	2.9	131
12	Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. <i>Lancet HIV</i> , 2021, 8, e554-e567.	2.1	105
13	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 896-907.	13.9	339
14	Regression discontinuity analysis demonstrated varied effect of Treat-All on CD4 testing among Southern African countries. <i>Journal of Clinical Epidemiology</i> , 2021, 140, 101-110.	2.4	1
15	The treatment gap for mental disorders in adults enrolled in HIV treatment programmes in South Africa: a cohort study using linked electronic health records. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e37.	1.8	20
16	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2313-2324.	13.9	108
17	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2325-2335.	13.9	112
18	Causes of infective endocarditis in the Western Cape, South Africa: a prospective cohort study using a set protocol for organism detection and central decision making by an endocarditis team. <i>BMJ Open</i> , 2021, 11, e053169.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Comparison of patients with severe COVID-19 admitted to an intensive care unit in South Africa during the first and second wave of the COVID-19 pandemic.. African Journal of Thoracic and Critical Care Medicine, 2021, 27, .	0.3	6
20	Trends in CD4 and viral load testing 2005 to 2018: multi-â€œcohort study of people living with HIV in Southern Africa. Journal of the International AIDS Society, 2020, 23, e25546.	1.2	27
21	Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records. The Lancet Global Health, 2020, 8, e1326-e1334.	2.9	40
22	Clinical evolution, management and outcomes of patients with COVID-19 admitted at Tygerberg Hospital, Cape Town, South Africa: a research protocol. BMJ Open, 2020, 10, e039455.	0.8	6
23	Leadership and early strategic response to the SARS-CoV- 2 pandemic at a COVID-19 designated hospital in South Africa. South African Medical Journal, 2020, 110, 463-465.	0.2	11
24	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893.	13.9	753
25	Characterizing the double-â€œsided cascade of care for adolescents living with HIV transitioning to adulthood across Southern Africa. Journal of the International AIDS Society, 2020, 23, e25447.	1.2	13
26	The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at Failure. American Journal of Epidemiology, 2020, 189, 811-819.	1.6	19
27	Recording of HIV Viral Loads and Viral Suppression in South African Patients Receiving Antiretroviral Treatment: A Multicentre Cohort Study. Antiviral Therapy, 2020, 25, 257-266.	0.6	7
28	Implementation of â€œTreat-â€œallâ€œ at adult <sc>HIV</sc> care and treatment sites in the Global le<sc>DEA</sc> Consortium: results from the Site Assessment Survey. Journal of the International AIDS Society, 2019, 22, e25331.	1.2	32
29	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
30	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	13.9	3,760
31	Extending Visit Intervals for Clinically Stable Patients on Antiretroviral Therapy: Multicohort Analysis of HIV Programs in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 439-447.	0.9	3
32	Seasonal variations in tuberculosis diagnosis among HIV-positive individuals in Southern Africa: analysis of cohort studies at antiretroviral treatment programmes. BMJ Open, 2018, 8, e017405.	0.8	5
33	Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 413-416.	0.9	2
34	Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. Journal of the International AIDS Society, 2018, 21, e25200.	1.2	6
35	Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. American Journal of Epidemiology, 2018, 187, 1990-2001.	1.6	8
36	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, 2018, 379, 1118-1127.	13.9	205

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 723-732.	13.9	480
38	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	2.9	44
39	Where do HIV-infected adolescents go after transfer? â€“ Tracking transition/transfer of HIV-infected adolescents using linkage of cohort data to a health information system platform. <i>Journal of the International AIDS Society</i> , 2017, 20, 21668.	1.2	45
40	Twelve-year mortality in adults initiating antiretroviral therapy in South Africa. <i>Journal of the International AIDS Society</i> , 2017, 20, 21902.	1.2	50
41	Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?. <i>Aids</i> , 2017, 31, 147-157.	1.0	12
42	HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapyâ€™Results From the leDEA Collaboration. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 319-329.	0.9	58
43	HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. <i>Journal of the International AIDS Society</i> , 2017, 20, 21327.	1.2	38
44	AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx186.	0.4	41
45	Record linkage augments cancer ascertainment in HIV cohorts in South Africa. <i>International Journal of Population Data Science</i> , 2017, 1, .	0.1	0
46	Life expectancy trends in adults on antiretroviral treatment in South Africa. <i>Aids</i> , 2016, 30, 2545-2550.	1.0	15
47	Incidence of AIDS-defining and Other Cancers in HIV-positive Children in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e164-e170.	1.1	38
48	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	2.9	20
49	CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 549-555.	2.0	34
50	A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment. <i>Journal of the International AIDS Society</i> , 2015, 18, 20628.	1.2	37
51	Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 146-154.	0.9	15
52	Implementation and Operational Research. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, e110-e119.	0.9	8
53	Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series. <i>Clinical Infectious Diseases</i> , 2015, 61, 1004-1012.	2.9	68
54	CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. <i>International Journal of Epidemiology</i> , 2015, 44, 251-263.	0.9	10

#	ARTICLE	IF	CITATIONS
55	Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study. <i>Lancet HIV</i> , 2015, 2, e368-e375.	2.1	29
56	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 30-38.	0.6	14
57	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e8-e16.	0.9	142
58	Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 547-554.	0.9	51
59	Kaposi's Sarcoma in HIV-Infected patients in South Africa: Multicohort study in the antiretroviral therapy era. <i>International Journal of Cancer</i> , 2014, 135, 2644-2652.	2.3	48
60	Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. <i>Tropical Medicine and International Health</i> , 2013, 18, 194-198.	1.0	20
61	Immune Recovery After Starting ART in HIV-Infected Patients Presenting and Not Presenting With Tuberculosis in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 142-145.	0.9	21
62	CD4 Count Slope and Mortality in HIV-Infected Patients on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 34-41.	0.9	21
63	Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies. <i>PLoS Medicine</i> , 2013, 10, e1001418.	3.9	330
64	A Dimorphic Fungus Causing Disseminated Infection in South Africa. <i>New England Journal of Medicine</i> , 2013, 369, 1416-1424.	13.9	118
65	Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa. <i>Antiviral Therapy</i> , 2013, 19, 521-525.	0.6	4
66	Zidovudine impairs immunological recovery on first-line antiretroviral therapy. <i>Aids</i> , 2013, 27, 2225-2232.	1.0	13
67	Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 428-437.	0.9	119
68	Tenofovir in Second-Line ART in Zambia and South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 41-48.	0.9	12
69	Invasive fungal infections, other than <i>Candida</i> and <i>Cryptococcus</i> , from 2008 to 2011, at Tygerberg Hospital in the Western Cape, South Africa. <i>International Journal of Infectious Diseases</i> , 2012, 16, e323.	1.5	0
70	Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. <i>PLoS Medicine</i> , 2012, 9, e1001304.	3.9	199
71	Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. <i>Aids</i> , 2011, 25, 1761-1769.	1.0	98
72	Incidence of Kaposi sarcoma in HIV-infected patients receiving antiretroviral therapy: A prospective multicohort study from southern Africa. <i>Journal of Clinical Oncology</i> , 2011, 29, 1589-1589.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007. <i>Aids</i> , 2010, 24, 2263-2270.	1.0	198
74	Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 524-532.	0.9	88
75	Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settings. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 775-783.	0.6	22
76	Combined Antiretroviral Treatment Initiation During Hospitalization: Outcomes in South African Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 51, 105-106.	0.9	6
77	PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 1125-1127.	1.1	44
78	Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the leDEA Southern Africa collaboration. <i>South African Medical Journal</i> , 2009, 99, 653-60.	0.2	44
79	Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. <i>BMC Public Health</i> , 2007, 7, 63.	1.2	160
80	A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. <i>New England Journal of Medicine</i> , 2001, 345, 1667-1675.	13.9	2,873
81	Early Surgery Determines Prognosis in Patients with IE: Outcome of Patients Managed by an Endocarditis Team - a Prospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0